Eisai to introduce breast cancer drug in India
The company will launch its novel anti-cancer drug Eribulin under the brand Halaven.
New Delhi, November 7, 2013: Japan’s Eisai Pharma plans to launch its novel anti-cancer drug Eribulin under the brand Halaven as part of its strategy to expand in the emerging markets. It may be noted here that Halaven is used in the treatment of third line metastatic breast cancer. The drug is expected to increase the life expectancy of the patients in the throes of the last stage.
The drug is priced at Rs 31,000 per vial, Eisai plans to experiment with differential pricing within the country. According to a research done by Frost & Sullivan, the oncology market in India is estimated to be close to Rs 700 crore and growing at 20 per cent.
The company believed that its differential pricing strategy will be a key to success in emerging markets.